Calton & Associates’s Editas Medicine EDIT Stock Holding History

Calton & Associates’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,420	Closed	-$105K	–	251
2023 Q3	$105K	Buy	+13,420	New	+$115K	0.15%	98

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Calton & Associates's EDIT Position: Q4 2023 in Review

Calton & Associates sold out of Editas Medicine (EDIT) in Q4 2023, closing a stake of 13,420 shares — an estimated $105K sold.

Calton & Associates first reported a position in EDIT in Q3 2023 and held it in 1 quarter. The position peaked at $105K in Q3 2023. 225 funds tracked by Wall St. Rank hold EDIT as of Q4 2023.

Calton & Associates reported no remaining Editas Medicine position as of Q4 2023 after selling out during the quarter.
Calton & Associates sold 13,420 Editas Medicine shares in Q4 2023, an estimated $105K.
Calton & Associates first reported a position in Editas Medicine in Q3 2023 and held it in 1 quarter.
Calton & Associates's Editas Medicine position peaked at $105K in Q3 2023.
225 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2023.

Based on Calton & Associates's 13F filing for Q4 2023, filed 7 Feb 2024.